Elanco Animal Health Incorporated announced on July 24, 2025, that Zenrelia (ilunocitinib) has received approval by the European Commission. This approval reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor for canine allergic dermatitis.
The EU approval represents a significant milestone in the European canine dermatology market, offering a new once-daily tablet solution for controlling pruritus and atopic dermatitis in dogs at least 12 months of age. Elanco's Dr. Ellen de Brabander noted that this makes Zenrelia its most rapidly expanding product globally.
Elanco plans to begin product launch immediately, with supply availability expected in the third quarter. Zenrelia joins Elanco's growing pet health portfolio in Europe, including AdTab, Credelio, and Galliprant, further solidifying its position as a leader in pet health innovation across the region.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.